The global diabetic macular edema market size is anticipated to be valued at USD 4.39 billion in 2025. It can touch a valuation of USD 5.93 billion by 2032. It can scale by exhibiting a CAGR of 4.4% during the forecast period (2025-2032).
Diabetic macular edema (DME) is a retinal disease identified by the swelling of the retina’s macula, that can lead to vision loss. Increased awareness of DME, combined with the high prevalence of diabetes globally, can drive the market growth.
Additionally, the introduction of anti-vascular endothelial growth factor (VEGF) and development of novel therapies for DME treatment can drive the market growth.
But the high costs of anti-VEGF therapies can hamper the market growth.
Key Market Insights
The diabetic macular edema market is expected to be marked by the adoption of bispecific antibody treatments and advances in ophthalmic imaging.
The full report is now available for purchase: https://www.coherentmi.com/industry-reports/diabetic-macular-edema-market
Diabetic Macular Edema Market Report Coverage
|
Report Coverage |
Details |
|
Market Revenue in 2025 |
USD 4.39 Billion |
|
Estimated Value by 2032 |
USD 5.93 Billion |
|
Growth Rate |
4.4% |
|
Historical Data |
2020–2024 |
|
Forecast Period |
2025–2032 |
|
Forecast Units |
Value (USD billion) |
|
Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
|
Segments Covered |
|
|
Geographies Covered |
North America (U.S. and Canada), Latin America (Brazil, Argentina, Mexico, and Rest of Latin America), Europe (Italy, Spain, U.K., Germany, France, Russia, and Rest of Europe), Asia Pacific (China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific), Middle East (GCC Countries, Israel, and Rest of Middle East), and Africa (South Africa, North Africa, and Central Africa) |
|
Growth Drivers |
|
|
Opportunities |
|
|
Trends |
|
|
Restraints & Challenges |
|
Market Dynamics
Concerns over vision-threatening diseases associated with diabetes are expected to drive the diabetic macular edema market growth. As per a report by the American Academy of Ophthalmology, 4.7% of the diabetic population in the U.S. were diagnosed with DEM. The report was published in July 2025, by sampling a medical claims database of patients covered by Medicare.
The use of second-generation anti-VEGF agents such as aflibercept, faricimab, and brolucizumab as a first-line treatment option can augur favorably for the market. The low inflammatory score and high efficacy can lead to its inclusion in combination therapies containing corticosteroids.
Market Opportunity: Optical Coherence Tomography (OCT) as a Guide for Prescribing Treatment
The recommendation of OCT for determining the inflammatory nature of the edema is estimated to be a prime growth opportunity in the market. Ophthalmologists can rely on parameters such as retinal volume and central subfield thickness (CST) to guide patients towards the right treatment. This can also assist machine-learning algorithms in determining DME patterns quickly and guide retina specialists in the decision to re-inject or shift to alternative drugs.
Market Challenge: Lack of Access to Authorized Drugs
Patients covered under Medicare are lacking access to FDA-approved drugs for the treatment of DME. This can be a cause for concern, as delays in the treatment can lead to vision loss. The use of prior authorization (PA) to determine the right treatment and coverage for patients can increase the economic burden on patients. All of these factors can impede the growth of the diabetes macular edema market.
Analyst’s View
Recent Developments
Celltrion, Inc. announced the approval of EYDENZELT (aflibercept-boav), a biosimilar to aflibercept, on October 10, 2025. This can help the company expand its offerings to patients with DME.
Competitor Insights
Market Segmentation
Regional Insights
Related Reports :